Related Experiment Video

Updated: Aug 2, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy

Y Hu1, J Lee, J A McCart

  • 1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Journal of Virology
|October 3, 2001
PubMed

Insights

Yaba-like disease virus shows promise as a cancer gene therapy vector, overcoming immunity to vaccinia virus. This novel poxvirus efficiently replicates in tumor cells and expresses transgenes, demonstrating potential in preclinical cancer models.

Area of Science:

  • Virology
  • Oncology
  • Gene Therapy

Background:

  • Vaccinia virus is a potential replicating vector for tumor-directed gene therapy.
  • Pre-existing immunity to vaccinia virus in cancer patients may limit its therapeutic application.
  • An alternative replicating poxvirus vector is needed to overcome immune limitations.

Purpose of the Study:

  • To investigate Yaba-like disease (YLD) virus as a novel replicating poxvirus vector for cancer gene therapy.
  • To assess YLD virus's immunologic profile, replication efficiency, and gene expression capabilities.
  • To evaluate YLD virus's efficacy in a preclinical cancer model.

Main Methods:

  • Assessed YLD virus cross-reactivity with vaccinia virus antibodies.
  • Determined YLD virus replication efficiency in human tumor cells.
  • Optimized YLD virus expansion and purification.
  • Utilized a shuttle plasmid for gene recombination (GFP).
  • Evaluated YLD virus-mediated gene delivery in a murine ovarian cancer model.

Main Results:

  • YLD virus demonstrated no cross-reactivity with vaccinia virus antibodies.
  • Efficient replication of YLD virus in human tumor cells was observed.
  • YLD virus was successfully expanded and purified to high titers.
  • The YLD virus RNA polymerase supported gene expression from a synthetic promoter.
  • In a murine ovarian cancer model, YLD virus delivered the GFP transgene to up to 38% of tumor cells.

Conclusions:

  • YLD virus exhibits favorable characteristics as a replicating vector for cancer gene therapy.
  • YLD virus overcomes pre-existing immunity associated with vaccinia virus.
  • Further exploration of YLD virus for cancer gene therapy is warranted.

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...